For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$2.62
Thesis
Perspective Therapeutics develops targeted alpha-particle radiopharmaceuticals built on lead-212, pairing a proprietary chelator technology with an isotope-supply position — a vertically integrated approach to the fast-emerging targeted-radiotherapy field that has drawn major pharma M&A.
This is a clinical-stage, pre-revenue position: the platform and isotope-supply angle are differentiated, but value depends on early-trial readouts across melanoma and neuroendocrine indications, manufacturing scale-up, and continued financing. Speculative, sized as an option on alpha-radiopharma clinical validation.
Catalysts
- Phase 1/2 readouts across lead programs
- Isotope-supply and manufacturing scale-up
- Partnership or pharma-interest signals in radiopharma
- Financing runway
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Sep 14OtherSEC
Filed 8-K with items 8.01 and 9.01.
- Aug 10Financial resultsSEC
8-K filing (items 2.02, 8.01, 9.01) disclosing financial results.
- Jun 1OtherSEC
8-K filing (items 8.01, 9.01) on 2026-06-01 disclosing other events.
- May 22OtherSEC
Filed 8-K on 2026-05-22 covering items 8.01 (other events) and 9.01.
- May 11Financial resultsSEC
8-K filing (items 2.02, 8.01, 9.01) reporting financial results.